Thermo Cardiosystems says HeartMate sales set for record:
This article was originally published in Clinica
Thermo Cardiosystems is predicting a buoyant fourth quarter with sales up more than 15% over the previous quarter to $17 million. Its HeartMate left ventricular assist system (LVAS) sales have risen over 35% in the same period, to $7 million. The HeartMate is the only LVAS system approved in the US. Thermo Cardiosystems, which is a subsidiary of Thermo Electron, reports its full year figures in February.
You may also be interested in...
Device Week, 4 December 2020 – MedWatch Question About Third-Party Servicers Slides Under Industry's Radar
On this week’s podcast: A change made by the US FDA to its MedWatch program that asks adverse event reporters whether a third party serviced a malfunctioning medical device went unnoticed by many in industry for nearly a year. We explain why, and tell how the servicer question will be helpful for manufacturers and the agency.
The series D financing will support the expansion of Everlywell’s consumer lab testing and digital health businesses.
New guidance from the UK regulator covers distribution and deployment of Pfizer/BioNTech's COVID-19 vaccine, which will be complex because of the temperature storage requirements and the large packs in which the vaccine doses will be delivered.